GeoVax Labs, Inc. (GOVX) AI Stock Analysis

GeoVax Labs, Inc., based in Smyrna, Georgia, is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies. Founded in 1988, the company utilizes a modified vaccinia ankara virus-like particle vaccine platform to combat infectious diseases and cancers. Its development portfolio includes preventive vaccines for COVID-19, HIV, Zika virus, malaria, and hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa. GeoVax Labs also develops therapeutic vaccines targeting HIV, chronic Hepatitis B, and solid tumor cancers. The company advances its pipeline through research collaborations with entities including NIAID, CDC, the U.S. Department of Defense, Emory University, University of Pittsburgh, and the Burnet Institute.

Revenue rose 55.0% to $1.8M in FY2020 before falling to $385,000 in FY2021 and $81,000 in FY2022. Revenue reached $4.0M in FY2024, representing growth of 4782.2%, but declined 37.1% to $2.5M in FY2025. In FY2025, gross margin was -628.0%, operating margin was -869.3%, and net income was -$21.5M, while research and development expenses totaled $18.1M. For the trailing twelve months ended June 30, 2026, revenue was $0, with quarterly revenue falling 100.0% year-over-year and trailing EPS at -$8.84.

As of June 30, 2026, GeoVax Labs held $3.1M in cash and short-term investments against total debt of $323,141, resulting in net cash of $2.8M. Total assets stood at $4.6M, shareholders' equity was $1.8M, and the current ratio was 1.54. In FY2025, operating cash flow was -$21.5M, free cash flow was -$21.5M, and capital expenditures were $27,612. Over a 5-year period, the company's share count increased by 970.6%.

GeoVax Labs has an enterprise value of $15.1M and a market capitalization of $2.4M. Its forward P/E of 9.7x trades below the 17.3x median of its US-listed Healthcare peers. The company has a price-to-sales ratio of 4.4x compared to the peer median of 4.1x, and an EV-to-EBITDA ratio of 15.3x versus the peer median of 12.0x. Over the past year, the stock fell 98.3%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock declined 100.0% while SPY gained 83.0%.

GeoVax Labs has 2 Strong Buy ratings from analysts, with no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $10.00, representing a 4096.4% premium over the October 16, 2026 close of $0.24. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$5.14. For the following fiscal year, two analysts estimate revenue of $0 and an EPS of -$2.85. The company beat EPS estimates in 2 of the last 4 quarters, with the next earnings release scheduled for November 12, 2026.

This page is an AI-written research summary of GeoVax Labs, Inc. (GOVX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GOVX income statement, GOVX balance sheet, GOVX key metrics, GOVX analyst forecast, GOVX chart. See the GOVX stock overview for the latest quote and news.